Acropolis Investment Management LLC Has $580,000 Position in Danaher Co. (NYSE:DHR)

Acropolis Investment Management LLC trimmed its holdings in Danaher Co. (NYSE:DHR) by 1.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,525 shares of the conglomerate’s stock after selling 43 shares during the quarter. Acropolis Investment Management LLC’s holdings in Danaher were worth $580,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Teachers Insurance & Annuity Association of America bought a new stake in Danaher in the third quarter worth approximately $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher during the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher in the 3rd quarter valued at $50,000. Darwin Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter valued at $55,000. Finally, Modus Advisors LLC bought a new position in Danaher during the fourth quarter worth $56,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $237.58 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market capitalization of $171.60 billion, a P/E ratio of 45.34, a P/E/G ratio of 4.32 and a beta of 0.83. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70. The business has a fifty day simple moving average of $235.27 and a two-hundred day simple moving average of $253.56.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 EPS. On average, analysts expect that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analyst Ratings Changes

DHR has been the subject of several research analyst reports. Stephens reaffirmed an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research report on Friday, December 13th. Citigroup cut their price target on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Finally, KeyCorp upped their target price on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.